

Curettage and cautery of skin conditions in general practice

Sir,

I would like to respond to Dr Jackson's letter (October *Journal*, p.435) about the use of curettage and cautery.

I have no figures for success rates but my impression is that it is high. It should be emphasized that follow up is easy in general practice and recurrence, if it does occur, usually as a small nodule, is easy to treat again. Further recurrence, certainly in basal cell carcinoma, is virtually unknown.

Squamous cell carcinoma is indeed potentially more invasive and should be treated by curettage and cautery, probably three times. The lesion should always be completely removed. There is no point in using curettage for biopsy only, and the inexperienced practitioner can easily become experienced. Once again, recurrences will almost certainly be infrequent and easier to treat.

Incidentally, histopathologists might report the original lesion as being incompletely removed in all cases. This does not mean that it will recur, only that an edge is not visible.

M M SUNDLE

Lane End House
25 Edgwarebury Lane
Edgware
Middlesex HA8 8LJ

GPs and work in the third world

Sir,

I read with interest the correspondence from Pearson¹ following Holden's paper on general practitioners working in the third world.²

I completed vocational training in 1984 with the specific intention of working overseas before returning to general practice in the United Kingdom. A very understanding surgeon taught me the basics of surgery for a year, and with some extra obstetrics and gynaecology experience, I went to western Nepal in 1989. The last two and a half years have been both testing and rewarding. In hindsight it seems that all aspects of my training have proved useful.

I have been working as the primary surgeon in a district of an estimated 500 000 people. 'Primary surgery' has become recognized as the second most important and cost effective type of health care in this part of the world.³ The first is, of course, community health care (clean water, mother and child health, im-

munization, nutrition education, family planning and treatment of acute infections, especially pneumonia). King, in his excellent writings on primary surgery, stated 'after the more useful drugs and vaccines, particularly the antibiotics, there are no more cost effective, or death-and-disability preventing methods than the simple forms of surgery.'³ Studies in rural Bangladesh and India have indicated that 10% of all deaths and almost 20% of deaths in young adults are the result of conditions that would be amenable to surgery in the industrial world, and even a simple surgical service would have prevented two thirds of these deaths.³

It is estimated that by the year 2000, 80% of the planet will be living in the developing world and therefore primary health care will increasingly be the health care for most of mankind.³ Although we have three western doctors here in Amp-Pipal with the MRCGP (among other qualifications) it is evident that for those willing to work overseas a period working in casualty, surgery and obstetrics is of great value. This can be during or after the vocational training period but requires the help and cooperation of our specialist colleagues. In the light of developments in the UK towards more surgery in general practice, the two aims could be linked. The Royal College of General Practitioners, together with the Royal College of Surgeons, could lead the way forward by creating a new level of certification to add integrity to this level of skill in primary surgery, perhaps the diploma of primary surgery.

GARY PARKES

Amp-Pipal Hospital
United Mission to Nepal
PO Box 126
Kathmandu
Nepal

References

1. Pearson CA. General practitioners and work in the third world [letter]. *Br J Gen Pract* 1991; 41: 304.
2. Holden JD. General practitioners and work in the third world. *Br J Gen Pract* 1991; 41: 163-165.
3. King M (ed). *Primary surgery. Volume 1. Non-trauma*. Oxford University Press, 1990.

Side effects of influenza vaccination

Sir,

I was interested to read the letter by Drs Robinson and Rayani (November *Journal*, p.476) regarding the side effects of influenza vaccine and their finding that 72 patients out of 120 (60%) reported not feeling ill after the vaccination. This con-

PRESCRIBING INFORMATION

Presentation: Lopid 300 capsules contain 300mg gemfibrozil; white powder in a No 0 capsule with a white body and maroon cap overprinted "LOPID 300". Lopid 600 tablets contain 600 mg gemfibrozil; white, elliptical tablets debossed "LOPID".

Indications: Primary prevention of coronary heart disease in men between 40 - 55 years of age with hyperlipidaemias who have not responded to diet and other appropriate measures. Dyslipidaemias of Fredrickson types IIa, IIb, III, IV, and V which do not respond adequately to diet alone. **Dosage and administration:** Adults: 1200mg daily in divided doses; usually twice daily. 900mg daily will prove sufficient in some patients and should be tried in the rare cases of intolerance at normal dosage. When maximum triglyceride reduction is desired, as in type V patients, up to 1500mg daily may be needed. *Elderly* (over 60 years): As for adults. *Children:* Not recommended. **Contra-indications:** Hypersensitivity to gemfibrozil, alcoholism, hepatic dysfunction, pre-existing gallstones. **Use in pregnancy:** Safe use in human pregnancy has not been established.

Precautions: Because long-term administration of Lopid is recommended, all baseline values, including lipid profile, blood count and liver function tests, should be measured before treatment and periodic determinations of serum lipids should be obtained. The drug should be withdrawn after 3 months if the response is inadequate or paradoxical. There have been reports of severe myositis with markedly elevated creatinine kinase and myoglobinuria (rhabdomyolysis) when Lopid and lovastatin were used concomitantly. Lopid may increase cholesterol excretion into the bile, raising the potential for gallstone formation. Lopid should be discontinued if gallstones are found. Significant mild haemoglobin haematocrit and white cell decreases have been observed. Eosinophilia has occasionally been reported. Rarely, severe anaemia, leucopenia, thrombocytopenia and bone marrow hypoplasia have been reported. Regular blood counts are recommended. Abnormal liver function tests have been observed. Liver function studies are recommended and treatment with Lopid terminated if abnormalities persist. Concomitant anticoagulant dosage may need to be reduced. Annual eye examination with an ophthalmoscope is recommended. **Warnings and adverse effects:** Significant side-effects were abdominal pain, diarrhoea, nausea, epigastric pain, vomiting and flatulence; occasionally and possibly attributable to Lopid were rash, dermatitis, pruritus, urticaria, impotence, headache, dizziness, blurred vision, painful extremities; rarely, myalgia accompanied by increases in creatine kinase. **Legal category:** POM. **Product Licence Nos:** 0018/0153/0157. **Product licence holder:** Parke, Davis & Co Ltd, Lambert Court, Chestnut Avenue, Eastleigh, Hants SO5 3ZQ. **Basic NHS cost:** Lopid 300 capsules, 100; £24.00. Lopid 600 tablets, 56 O.P.D. pack; £26.88.

References

1. Manninen V, Elo O, Frick MH et al. *JAMA* 1988; 260: 641-651.
2. Lipids Research Clinics Program. *JAMA* 1984; 251 (3):351-374.
3. *Brit Heart J* 1978; 40: 1069-1118.

† In years 4 to 5 of the Helsinki Heart Study, Lopid showed a 50% reduction in fatal and non-fatal myocardial infarction and sudden death, compared with placebo. Lopid is indicated for the primary prevention of coronary heart disease in men between 40 to 55 years of age with hyperlipidaemias who have not responded to diet and other appropriate measures. Lopid is not indicated for use in children under the age of 12.

Further information is available from Parke-Davis Research Laboratories, Lambert Court, Chestnut Avenue, Eastleigh, Hampshire SO5 3ZQ. Telephone (0703) 620500.

PARKE-DAVIS RESEARCH LABORATORIES

© Parke-Davis Research Laboratories 1991.

* Trade mark

Z159-UK-Mar 91